Introduction {#tca13260-sec-0005}
============

Bronchopulmonary large cell neuroendocrine carcinomas (LCNEC) comprise approximately 3% of malignant lung neoplasms.[1](#tca13260-bib-0001){ref-type="ref"} Similar to small cell lung carcinoma (SCLC), LCNEC is of neuroendocrine derivation; however, it is most commonly classified as a form of non‐small cell lung cancer (NSCLC). Considering the high grade nature of LCNEC, patients often present with locally advanced or metastatic disease.[2](#tca13260-bib-0002){ref-type="ref"} Given the rarity of early stage disease, highly powered studies are lacking as are consensus recommendations regarding treatment. Additionally, the discordance between embryologic origin and oncologic classification of LCNEC complicate matters further as treatment paradigms for SCLC and NSCLC differ significantly.

In early stage NSCLC, long‐term survival data has established surgical resection; either lobectomy or pneumonectomy as the standard of care.[3](#tca13260-bib-0003){ref-type="ref"} As LCNEC is classified under NSCLC, surgical management is recommended when LCNEC is diagnosed early (ie, stage I or II disease).[4](#tca13260-bib-0004){ref-type="ref"} However, a proportion of patients may be medically and/or technically inoperable, or refuse surgery altogether. In these circumstances, stereotactic body radiation therapy (SBRT) is a local modality that affords high local control and satisfactory outcomes for inoperable early‐stage non‐small cell lung cancer (NSCLC).[5](#tca13260-bib-0005){ref-type="ref"} SBRT experiences for early‐stage LCNEC tumors have been limited to two case reports.[6](#tca13260-bib-0006){ref-type="ref"}, [7](#tca13260-bib-0007){ref-type="ref"} Furthermore, SBRT has not previously been compared with the current standard of surgical resection. As a result, we sought to compare these modalities using a large, contemporary national database to compare treatment approaches and outcomes in T1‐2N0 LCNEC.

Methods {#tca13260-sec-0006}
=======

The NCDB is a joint project managed by the Commission on Cancer (CoC), American College of Surgeons, and the American Cancer Society. Information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the United States annual oncologic cases have been captured within the dataset.[8](#tca13260-bib-0008){ref-type="ref"} The American College of Surgeons and the CoC have not verified and are neither responsible for the statistical and analytical methodology employed nor the conclusions drawn from these data. All data including patient information in the NCDB database has been excluded from this study and it was exempt from institutional review board evaluation.

The NCDB 2004 to 2015 Participant User File containing Large cell neuroendocrine carcinomas (LCNEC) histology code 8012/3 was utilized for this study. Inclusion criteria for this investigation were patients with newly‐diagnosed, histologically‐confirmed T1‐2N0M0 LCNEC tumors. Those patients who received no treatment were excluded, as were those who received nonablative radiotherapy (RT) and postoperative RT. In addition to removing patients with no follow‐up information, subjects with \<one month follow‐up were also excluded to account for immortal time bias.

Radiation technique was recorded in the NCDB, and was limited to a dose of 48--60 Gy in 3--5 fractions.[9](#tca13260-bib-0009){ref-type="ref"} Surgery was defined as pneumonectomy, bi/lobectomy, or sublobar resection (eg, wedge resection or segmentectomy), all of which are coded for in the NCDB.

Information collected on each patient encompassed demographic, clinical, and treatment data. Statistical analysis was performed via MedCalc Version 18 (Ostend, Belgium). Chi‐square testing was used to compare clinical, socioeconomic and treatment characteristics between the surgical and SBRT groups. Summary statistics were reported for discrete variables and multivariable logistic regression models were used to assess the association between independent variables of interest. Overall survival (OS) was calculated from the date of diagnosis to the date of last contact or death.[10](#tca13260-bib-0010){ref-type="ref"} Univariable survival analysis was performed for all characteristics listed on Table [1](#tca13260-tbl-0001){ref-type="table"}, and statistically significant factors were then entered in a hierarchical fashion using "enter" selection of the covariates\' likelihood ratios, adjusted hazard ratios (HR) and 95% confidence interval (CI) were reported, with α = 0.05 used to indicate statistical significance.

###### 

Patient characteristics (*n* = 3209)

  Characteristics                            No. (%)
  ---------------------------------------- -----------
  Age                                      
  ≤68                                       1712 (53)
  \>68                                      1497 (47)
  Chemotherapy                             
  No                                        2436 (76)
  Yes                                       773 (24)
  Comorbidity score                        
  0                                         1480 (46)
  1                                         1250 (39)
  ≥2                                        480 (15)
  Distance                                 
  ≤11 miles                                 1563 (49)
  \>11 miles                                1646 (51)
  Facility type                            
  Community Cancer Program                   236 (7)
  Comprehensive Community Cancer Program    1518 (47)
  Academic/Research Program                 1455 (46)
  Grade                                    
  Well differentiated                        18 (1)
  Moderately differentiated                  129 (5)
  Poorly differentiated                     2533 (94)
  Education, %                             
  ≥29                                       595 (19)
  20--28.9                                  991 (31)
  14--19.9                                  1031 (32)
  \<14                                      592 (18)
  Income, USD                              
  \<30 000                                  652 (20)
  30 000--35 000                            866 (27)
  35 000--45 999                            875 (27)
  \>46 000                                  816 (26)
  Insurance                                
  None                                       67 (2)
  Private                                   986 (31)
  Government                                2124 (67)
  Location                                 
  Metropolitan                              2585 (81)
  Urban                                     547 (17)
  Rural                                      77 (2)
  Race                                     
  Caucasian                                 2832 (88)
  African American                           303 (9)
  Other                                      74 (3)
  Gender                                   
  Male                                      1674 (52)
  Female                                    1535 (48)
  T Stage                                  
  T1                                        1893 (59)
  T2                                        1316 (41)
  Year                                     
  2004--2006                                688 (21)
  2007--2009                                1075 (33)
  2010--2012                                903 (28)
  2013--2014                                544 (18)

Propensity score analysis was used to mitigate indication bias caused by lack of randomization.[11](#tca13260-bib-0011){ref-type="ref"}, [12](#tca13260-bib-0012){ref-type="ref"}, [13](#tca13260-bib-0013){ref-type="ref"} Multivariable logistic regression was used to calculate the propensity score providing a score reflecting the conditional probability of a patient receiving of surgery or SBRT. After calculation of the propensity score, a Cox proportional hazards model with adjustment for propensity score was developed.[14](#tca13260-bib-0014){ref-type="ref"} Patients treated with SBRT were also matched with patients treated surgically based on the propensity score using an exact match resulting in 238 pairs. Kaplan‐Meier analysis was then used to compare outcomes between these two propensity matched cohorts. In addition, to demonstrating that the groups were balanced, we sorted the matched cohorts by propensity score and compared the means of the quintiles which indicated a difference of less than 0.10.

Results {#tca13260-sec-0007}
=======

In summary, 39 036 patients were diagnosed with bronchopulmonary large cell neuroendocrine carcinomas (LCNEC), 6661 of these patients were staged as T1‐2N0M0 (see Figure [1](#tca13260-fig-0001){ref-type="fig"} for all inclusion criteria). Of those patients, 2971 (93%) underwent resection and 238 (7%) received SBRT. Of the patients that received SBRT, reasons for not undergoing surgery were as follow: comorbid conditions (*n* = 65 \[27%\]), patient refusal despite recommendation (n = 15 \[6%\]), and the remainder for unknown reasons. The median SBRT dose was 50 Gy (IQR: 48--60) in four fractions (3--5). There were slightly more male patients (52%) and the majority of patients had T1 disease 1893 (59%). A full set of baseline characteristics are given in Table [1](#tca13260-tbl-0001){ref-type="table"}.

![CONSORT diagram showing selection criteria.](TCA-11-305-g001){#tca13260-fig-0001}

Multivariable logistic regression was performed to evaluate independent predictors of receiving SBRT and those results are displayed in Table [2](#tca13260-tbl-0002){ref-type="table"}. SBRT patients were older (*P* \< 0.0002) and had lower comorbidity scores (*P* \< 0.0093). The median follow‐up for the entire cohort was 39 months. Predictors of decreased OS on multivariable analysis are listed in Table [3](#tca13260-tbl-0003){ref-type="table"} and include older age, higher comorbidity score, male sex, higher T stage, and treatment with SBRT. As described in Methods, after propensity matching, Kaplan‐Meier analysis was used to compare OS in 238 matched pairs having received resection *v*ersus SBRT (Fig [2](#tca13260-fig-0002){ref-type="fig"}). Median survival was 34.6 months in the SBRT group and 57.2 months in the surgical group with corresponding five‐year OS of 25% versu*s* 48% (*P* \< 0.0001). In the unmatched cohorts, overall survival was a median of 68.2 months compared to 34.6 months, again in favor of surgical resection (*P* \< 0.0001). Corresponding five year overall survivals were 53% and 24%.

###### 

Multivariable logistic regression for receipt of Stereotactic body radiotherapy (SBRT)

  Characteristic                            Odds ratio (95% CI)    *P*‐value
  ---------------------------------------- --------------------- --------------
  Age                                                            
  ≤68                                            Reference       
  \>68                                       1.88 (1.34--2.62)     **0.0002**
  Chemotherapy                                                   
  No                                             Reference       
  Yes                                        0.35 (0.21--0.57)    **\<0.0001**
  Comorbidity score                                              
  0                                              Reference       
  1                                          0.36 (0.26--0.51)    **\<0.0001**
  ≥2                                         0.57 (0.38--0.87)     **0.0093**
  Distance                                                       
  ≤11 miles                                      Reference       
  \>11 miles                                 1.22 (0.88--1.69)       0.2276
  Facility type                                                  
  Community Cancer Program                       Reference       
  Comprehensive Community Cancer Program     2.54 (1.17--5.50)     **0.0179**
  Academic/Research Program                  2.00 (0.92--4.37)       0.0807
  Grade                                                          
  Well differentiated                            Reference       
  Moderately differentiated                  0.31 (0.02--4.01)       0.3726
  Poorly differentiated                      0.89 (0.11--7.48)       0.9149
  Education, %                                                   
  ≥29                                            Reference       
  20--28.9                                   1.00 (0.86--1.17)        0.94
  14--19.9                                   0.92 (0.78--1.09)        0.35
  \<14                                       0.85 (0.69--1.05)        0.14
  Income, USD                                                    
  \<30 000                                       Reference       
  30 000--35 000                             0.97 (0.59--1.57)       0.8896
  35 000--45 999                             1.04 (0.61--1.75)       0.8916
  \>46 000                                   0.60 (0.33--1.11)       0.1025
  Insurance                                                      
  None                                           Reference       
  Private                                    0.80 (0.55--1.18)        0.26
  Government                                 1.06 (0.73--1.55)        0.76
  Location                                                       
  Metropolitan                                   Reference       
  Urban                                      0.95 (0.60--1.49)       0.8080
  Rural                                      2.01 (0.92--4.39)       0.0796
  Race                                                           
  Caucasian                                      Reference       
  African American                           1.62 (1.00--2.61)     **0.0499**
  Other                                      0.62 (0.21--1.85)       0.3896
  Gender                                                         
  Male                                           Reference       
  Female                                     0.94 (0.70--1.25)       0.6559
  T Stage                                                        
  T1                                             Reference       
  T2                                         0.68 (0.49--0.94)     **0.0185**
  Year                                                           
  2004--2006                                     Reference       
  2007--2009                                 4.06 (2.32--7.08)    **\<0.0001**
  2010--2012                                 4.19 (2.37--7.39)    **\<0.0001**
  2013--2014                                 5.49 (3.05--9.89)    **\<0.0001**

bold values=statistically significant.

###### 

Multivariable cox regression

  Characteristic          HR (95% CI)      *P*‐value
  ------------------- ------------------- -----------
  Age                                     
  ≤68                      Reference      
  \>68                 1.44 (1.29--1.60)   \<0.0001
  Chemotherapy                            
  No                       Reference      
  Yes                  0.83 (0.73--0.94)    0.0029
  Comorbidity score                       
  0                        Reference      
  1                    1.12 (1.01--1.25)    0.0344
  ≥2                   1.45 (1.27--1.66)   \<0.0001
  Treatment                               
  Surgery                  Reference      
  SABR                 1.61 (1.36--1.92)   \<0.0001
  Race                                    
  Caucasian                Reference      
  African American     0.80 (0.66--0.97)    0.0201
  Other                0.80 (0.57--1.11)    0.1861
  Gender                                  
  Male                     Reference      
  Female               0.83 (0.75--0.92)    0.0002
  T stage                                 
  T1                       Reference      
  T2                   1.26 (1.14--1.40)   \<0.0001

![Median survival was 34.6 months in the stereotactic body radiotherapy (SBRT) group and 57.2 months in the surgical group with corresponding five‐year OS of 25% versus 48% (*P* \< 0.0001). Treatment (![](TCA-11-305-g003.jpg "image")) surgery and (![](TCA-11-305-g004.jpg "image")) SABR.](TCA-11-305-g002){#tca13260-fig-0002}

Discussion {#tca13260-sec-0008}
==========

In this investigation, we utilized the NCDB to compare outcomes following surgery and SBRT for early stage large cell neuroendocrine carcinomas (LCNEC) and the results indicate that surgery continues to be the standard for patients who are candidates for resection. However, definitive SBRT does appear to provide a viable alternative for patients in whom surgery is not possible. Keeping in mind the rarity of LCNEC, randomized studies would likely suffer from inadequate accrual therefore are unlikely to occur. Further retrospective studies, however, could be helpful in evaluating cancer‐related endpoints such as, patterns of failure and salvage therapy.

As alluded to above, due to the rarity of LCNEC there is no defined optimal treatment which is supported by large randomized trials.[15](#tca13260-bib-0015){ref-type="ref"} Treatment for LCNEC has long been a hybrid of the regimen for non‐small cell lung cancer and small‐cell lung cancer. For example, cases of operable nonmetastatic LCNEC should undergo surgical resection, similar to NSCLC. Conversely, chemotherapeutic regimens, when offered, are comparable to that of a SCLC regimen.[16](#tca13260-bib-0016){ref-type="ref"} In terms of surgery, a recent study comparing sublobar resection (SLR) versus lobectomy for early stage LCNEC utilizing NCDB data found the five year survival to be 38% for both groups and 37.8% and 56.7% (*P* \< 0.001), respectively.[17](#tca13260-bib-0017){ref-type="ref"} In another study, data from SEER for patients with early stage LCNEC that underwent resection showed the median survival was 48 months (*P* = 0.000).[3](#tca13260-bib-0003){ref-type="ref"} These results are in line with those herein as we found a similar five year survival of 48% and a median survival of 57.2 months in our study.

Only two case reports regarding early stage LCNEC treatment with SBRT were found on review of the literature. The first case was a 54 year old female who underwent a wedge resection and mediastinal lymph node dissection for a left upper lobe nodule and was diagnosed with a stage 1 LCNEC. The patient later developed a growing nodule in the left upper lobe which was PET‐avid, and after multidisciplinary discussion underwent SBRT. She received 50 Gy in five fractions and at four months post SBRT, there was no evidence of local or distant failure. The second case report involved a 78 year old male with multiple comorbidities who was found to have stage IA LCNEC of the left upper lobe, diagnosed by percutaneous needle biopsy. Surgery was recommended; however, SBRT (55 Gy in five fractions) was the chosen treatment due to the patient\'s reluctance to undergo surgery. At last follow up, (18 months) there was no evidence of disease and no treatment‐related toxicity.

NCDB‐based studies have inherent limitations since the data does not contain important endpoints such as local failure, distant failure, or treatment related toxicity all of which impact on a generally frail patient population. In this study, the SBRT group was an older cohort, and as such are likely to be other unrecorded biases that could potentially create an imbalance between the groups. In addition, the NCDB is lacking data on performance status, extent of clinical workup, baseline pulmonary function, and salvage therapies, all of which would impact the ultimate outcome in these patients. The above limitations need to be accounted for when interpreting the results of the present study, and hopefully will help generate retrospective investigations that better characterize outcomes in this patient population.

In conclusion, the results presented here suggest that surgical resection is the cornerstone of therapy for early stage LCNEC. In situations where surgery is not feasible, SBRT is a viable alternative.
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